




The relative strengths and weaknesses of Syros Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Syros Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 301%, being 49% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	73,159
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,413
Liabilities, Non-Current	0
Other Assets	1,391
Other Compr. Net Income	-33
Other Expenses	0
Other Liabilities	0
Other Net Income	1,777
Other Revenues	0
Property and Equipment	3,938
Research and Development	41,896
Selling, General and Administrative Expense	13,891

Output Variable	Value in 1000 USD
Assets	78,488
Liabilities	12,413
Expenses	55,787
Revenues	0
Stockholders Equity	66,075
Net Income	-54,010
Comprehensive Net Income	-54,026
BaseVar	74,249
ECR before LimitedLiability	198%
Economic Capital Ratio	301%